Cannabidiol (CBD) is one of 113 cannabinoids that have been identified in cannabis. In a series of letters to distributors and producers of the substance, the government’s Medicines and Healthcare Products Regulatory Agency (MHRA) advised that CBD is being designated as a medicine and sale of it must stop within 28 days.
That would mean CBD now falls under the following definition of a ‘medicinal product’:
(a) Any substance or combination of substances presented as having properties for treating or preventing disease in human beings; or
(b) Any substance or combination of substances which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.
And MHRA confirmed the same:
But unfortunately, consumers will have to wait while the government has placed a halt on sales. This is because CBD must adhere to certain regulatory procedures now that it is classed as medicinal:
Regulation of CBD is essential but sudden regulation like this will harm many legitimate retailers and effect consumers the most. The costs involved with attaining a licence will only pave the way for big pharma to monopolise on CBD.
Peter Reynolds, President of CLEAR Cannabis Law Reform, told The Canary that the impact will be “catastrophic” in the short term because it denies hundreds of thousands of people the medicine and food supplements they need. But in the long term, he hailed the policy as a step closer to a regulated cannabis industry.